The models allowed to assess the anti-lymphoma effects of the anti-CD30 ADC brentuximab-vedotin and to verify the synergistic effect of ADAM-10 inhibitors, which increase CD30 surface expression in tumor cells by preventing its shedding [97]. The gene discussed is TNFRSF8; the disease is neoplasm.